摘要
Abstract
Objective To observe the efficacy of different closes of recombinant human tumor necrosis factor receptor type Ⅱ-Fc fusion protein(rhTNFR;Fc) in treating rheumatoid arthritis(RA) and to understand the advantages and disadvantages of different doses and different usages to provide the basis for clinical medication. Methods 60 patients with RA were equally divided into 3 groups. The low dose group was given rhTNFR:Fc 25mg each time,twice per week,the middle dose group was given rhTNFR:Fc 37. 5mg each time,once per week and the high dose group was given rhTNFR:Fc 50mg each time, once per week. Methotrexate 10mg was weekly given in 3 groups. All cases were performed the related examinations at different time points(0 ,4 , 8 ,12 weeks) before and after treatment, including the Disease Activity Score(DAS28) , the visual analogue scale( VAS) , erythrocyte sedimentation rate(ESR) ,C-reactive protein(CRP) ,rheumatoid factor(RF) ,anticyclic citrullinated peptide antibody(CCP). The change of related indexes of joint function before and after treatment in 3 groups were observed and evaluated. Results The comparison of detection results of related joint function indexes before and after treatment showed statistical difference among 3 groups(P<0. 01). Comparing the detection results of related joint function indexes demonstrated statistical difference among different treatment dura-tions(P<0. 01). Conclusion Using rhTNFR:Fc to treat RA can improve symptoms and signs effectively, but the dose and treatment cycle should be selected according to the actual clinical conditions,treatment goals and the treatment cost.关键词
受体,肿瘤坏死因子/重组融合蛋白质类/关节炎,类风湿Key words
receptors,tumor necrosis factor/recombinant fusion proteins/arthritis,rheumatoid
